CLL

Conference Coverage

CLL: The initial work-up

CHICAGO – Molecular testing has prognostic value, but still doesn’t drive treatment under updated iwCLL guidelines.

MD IQ

News from the FDA/CDC

Venetoclax label now includes MRD data

The MURANO trial showed high rates of minimal residual disease negativity in patients treated with the venetoclax combination.

Pages